The EU-funded consortium Exscalate4CoV just announced that an already registered generic drug used to treat osteoporosis, Raloxifene, could be an effective treatment for COVID-19 positive patients with mild or asymptomatic infection. The consortium is using an EU-backed supercomputing platform, one of the world’s most powerful, to check the potential impact of known molecules against the genomic structure of coronavirus.

This is one of many examples of how the EU’s research and innovation programme Horizon 2020 is bringing together the best of European researchers, pharmaceutical companies, technologies and research infrastructures to contribute to defeating the virus.